ESSA Pharma Inc

NASDAQ EPIX

Data sourced from iex and EODHD
Download Data

ESSA Pharma Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2024: USD 0.00

ESSA Pharma Inc Revenue is USD 0.00 for the Trailing 12 Months (TTM) ending March 31, 2024, a 0.00% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • ESSA Pharma Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.00, a 0.00% change year over year.
  • ESSA Pharma Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
  • ESSA Pharma Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
  • ESSA Pharma Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 0.00, a 0.00% change year over year.
NASDAQ: EPIX

ESSA Pharma Inc

CEO Dr. David Ross Parkinson M.D.
IPO Date July 9, 2015
Location Canada
Headquarters 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Employees 50
Sector Healthcare
Industry Biotechnology
Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

StockViz Staff

September 20, 2024

Any question? Send us an email